Page last updated: 2024-11-13

1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

**1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine (PGPC)** is a synthetic phospholipid analog. It is a modified version of phosphatidylcholine (PC), a major component of cell membranes.

**Structure:**

* **Palmitoyl (16:0):** A saturated fatty acid chain with 16 carbon atoms.
* **Glutaroyl (5:0):** A saturated fatty acid chain with 5 carbon atoms.
* **Glycerol:** A three-carbon alcohol.
* **Phosphorylcholine:** A phosphate group linked to choline.

**Importance for Research:**

**1. Cell Membrane Research:**

* PGPC can be used as a tool to study the properties and functions of cell membranes.
* It can be incorporated into artificial membranes (liposomes) to create model systems for studying membrane transport, protein interactions, and other processes.

**2. Drug Delivery Systems:**

* PGPC has been investigated as a potential carrier for drug delivery.
* Its unique chemical structure and ability to interact with cell membranes make it suitable for encapsulating and delivering drugs.

**3. Neurological Research:**

* PGPC has shown potential benefits in the treatment of neurological disorders, such as Alzheimer's disease and Parkinson's disease.
* It has been reported to protect neurons from damage and improve cognitive function.

**4. Inflammation and Immunology:**

* PGPC has anti-inflammatory properties.
* It has been shown to inhibit the production of inflammatory mediators and reduce inflammation in animal models.

**5. Anti-cancer Activity:**

* Some studies suggest that PGPC may have anti-cancer activity.
* It has been shown to inhibit the growth of certain cancer cells.

**6. Other Applications:**

* PGPC has also been investigated for its potential use in cosmetics, food additives, and other applications.

**Conclusion:**

PGPC is a versatile phospholipid analog that has numerous applications in research. Its unique structure and biological properties make it a valuable tool for studying cell membranes, developing drug delivery systems, and exploring new therapeutic strategies for various diseases.

2-O-glutaroyl-1-O-palmitoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine having palmitoyl and glutaroyl groups at positions 1 and 2 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID46907872
CHEBI ID61822
SCHEMBL ID22607951
MeSH IDM0350275

Synonyms (24)

Synonym
pc(16:0/5:0(cooh))
LMGP20010006
1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine
1-hexadecanoyl-2-glutaroyl-sn-glycero-3-phosphocholine
pgpc
1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine
1-o-palmitoyl-2-o-glutaroyl-sn-glycero-3-phosphocholine
1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine
(2r)-2-[(4-carboxybutanoyl)oxy]-3-(palmitoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
1-palmitoyl-2-glutaryl-glycerophosphocholine
1-o-palmitoyl-2-o-glutaryl-sn-glycero-3-phosphocholine
2-o-glutaryl-1-o-palmitoyl-sn-glycero-3-phosphocholine
CHEBI:61822 ,
2-o-glutaroyl-1-o-palmitoyl-sn-glycero-3-phosphocholine
EPITOPE ID:153524
DTXSID50677185
(2r)-2-[(4-carboxybutanoyl)oxy]-3-(hexadecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
pgpc, 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine, powder
pgpc, 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine, chloroform
Q27131426
CDZVJFRXJAUXPP-AREMUKBSSA-N
1- palmitoyl- 2- glutaryl phosphatidylcholine
SCHEMBL22607951
AKOS040754955

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The toxic lipid effects include inflammation and under sustained exposure apoptosis."( Toxicity of oxidized phosphatidylcholines in cultured human melanoma cells.
Hermetter, A; Hofmann-Wellenhof, R; Jaritz, H; Köfeler, H; Ramprecht, C; Schaider, H; Streith, I; Zenzmaier, E, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" We found a dose-response relationship for mGFP-GPI nanoplatform disintegration upon addition of POVPC, correlating with the signal of the apoptosis marker Annexin V-Cy3."( Oxidized Phospholipids Inhibit the Formation of Cholesterol-Dependent Plasma Membrane Nanoplatforms.
Brameshuber, M; Deigner, HP; Hermetter, A; Manner, C; Peksel, B; Péter, M; Rossboth, BK; Schütz, GJ; Sevcsik, E; Török, Z, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,2-diacyl-sn-glycero-3-phosphocholineThe conjugate base of a 1,2-diacyl-sn-glycero-3-phosphocholine compound formed by deprotonation of the phosphate OH group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (42.86)29.6817
2010's11 (52.38)24.3611
2020's1 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.85 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.76%)5.53%
Reviews2 (9.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]